RAPT Therapeutics' Acquisition by GSK and Its Impact on Stock Performance

Core Insights - RAPT Therapeutics is a biopharmaceutical company focused on developing treatments for inflammatory and immunologic diseases, particularly severe food allergies [1] - The company's leading drug, ozureprubart, is currently in mid-stage clinical trials in the US [1] Acquisition Details - RAPT's shares surged by 64% to $57 following the announcement of its acquisition by GSK, valued at approximately $2.2 billion [3] - GSK will pay $58.00 per share, providing access to RAPT's promising food allergy treatment, ozureprubart, which is in phase 2b clinical development [3][4] - The acquisition marks the first major deal under GSK's new CEO, Luke Miels, with an upfront payment of $1.9 billion, net of cash acquired [4] Stock Performance - RAPT's stock is currently trading at $57.56, reflecting a significant increase of 63.97% with a change of $22.46 [5] - The stock's price has ranged from a low of $57.46 to a high of $57.61, marking its highest price in the past year [5] - The company's market capitalization stands at approximately $951.8 million, with a trading volume of 29,635,290 shares [5]